Starting on:
May 6, 2021
Ending on:
May 6, 2021
Moderator(s):
Venue:
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
May 6, 2021
Ending on:
May 6, 2021
Moderator(s):
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
JOURNAL CLUB - 06/05/2021
Starting on:
May 6, 2021 8:00 AM
May 6, 2021 8:00 AM
Ending on:
May 6, 2021 9:30 AM
May 6, 2021 9:30 AM
Venue:
THE KAREN HOSPITAL
THE KAREN HOSPITAL
Description
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Objectives
- Ivabradine should be considered to reduce the risk of HF hospitalization in patients in sinus rhythm with an EF â?¤ 35%, a heart rate remaining â?¥ 70bpm and persisting symptoms (NYHA class II-IV) despite treatment with evidence-based dose of beta blocker (or maximum tolerated dose below that), ACE inhibitor (or ARB), and an MRA (or ARB) (class IIa, level B).
- Ivabradine may be considered to reduce the risk of HF hospitalization in patients in sinus rhythm with an EF â?¤ 35% and a heart rate â?¥ 70bpm who are unable to tolerate a beta-blocker. Patients should also receive an ACE inhibitor (or ARB) and an MRA (or ARB). (class IIb, level C).
- Most cardiovascular endpoints (death from heart failure, hospital admission for heart failure, any cardiovascular admission, and the secondary composite of cardiovascular death, hospital admission for heart failure, or non-fatal myocardial infarction) were significantly reduced by ivabradine.
Presenters
-
Dr.
JANE WAVINYA
MEDICAL OFFICER
The Karen Hospital -
Dr.
LAMIN JAITEH
MEDICAL OFFICER
The Karen Hospital